WallStSmart

Intercontinental Exchange Inc (ICE)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 530% more annual revenue ($62.58B vs $9.93B). ICE leads profitability with a 33.4% profit margin vs 12.4%. ICE appears more attractively valued with a PEG of 2.20. ICE earns a higher WallStSmart Score of 63/100 (C+).

ICE

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 7.5Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 0.60

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICEUndervalued (+38.6%)

Margin of Safety

+38.6%

Fair Value

$255.26

Current Price

$156.83

$98.43 discount

UndervaluedFair: $255.26Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICE5 strengths · Avg: 9.0/10
Profit MarginProfitability
33.4%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
49.6%10/10

Strong operational efficiency at 49.6%

Market CapQuality
$88.85B9/10

Large-cap with strong market position

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Free Cash FlowQuality
$1.11B8/10

Generating 1.1B in free cash flow

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

ICE3 concerns · Avg: 3.3/10
PEG RatioValuation
2.204/10

Expensive relative to growth rate

P/E RatioValuation
27.0x4/10

Moderate valuation

Altman Z-ScoreHealth
0.602/10

Distress zone — elevated risk

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ICE

The strongest argument for ICE centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 33.4% and operating margin at 49.6%.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ICE

The primary concerns for ICE are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

ICE profiles as a mature stock while PFE is a declining play — different risk/reward profiles.

ICE carries more volatility with a beta of 1.05 — expect wider price swings.

ICE is growing revenue faster at 7.8% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ICE scores higher overall (63/100 vs 49/100), backed by strong 33.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intercontinental Exchange Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

The Intercontinental Exchange (ICE) is an American Fortune 500 company formed in 2000 that operates global exchanges, clearing houses and provides mortgage technology, data and listing services. The company owns exchanges for financial and commodity markets, and operates regulated exchanges and marketplaces.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?